MAbs

Vir Biotechnology Announces New Preclinical Research Demonstrating VIR-7831 Maintains Neutralizing Activity Against the SARS-CoV-2 California Variant

Retrieved on: 
Monday, April 5, 2021
Medical specialties, Immunology, Medicine, Clinical medicine, Biotechnology, Immune system, Monoclonal antibody, Neutralizing antibody, Neutralization, Antibody, MAbs

Data were published on April 1, 2021 on bioRxiv , and have been submitted to a peer-reviewed journal for future print publication.

Key Points: 
  • Data were published on April 1, 2021 on bioRxiv , and have been submitted to a peer-reviewed journal for future print publication.
  • In addition, the L452R mutation reduced the neutralization activity of 14 out of 35 RBD-specific mAbs, including three clinical-stage antibodies.
  • Researchers also observed a complete loss of neutralization by all NTD-specific mAbs that is mediated by an unconventional escape mechanism.
  • Vir Biotechnologyis a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases.

Y-mAbs Announces 2020 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, February 25, 2021
Medical specialties, Clinical medicine, Medicine, Immunology, Priority review, Biotechnology, Neuroblastoma, School voucher, MAbs, Monoclonal antibody

We are pleased with our 2020 financial results, especially seen in conjunction with the approval of DANYELZA, and the sale of our Priority Review Voucher for $105 million.

Key Points: 
  • We are pleased with our 2020 financial results, especially seen in conjunction with the approval of DANYELZA, and the sale of our Priority Review Voucher for $105 million.
  • On December 28, 2020 Y-mAbs announced that it entered into a definitive agreement to sell its DANYELZA Priority Review Voucher to United Therapeutics Corporation for $105 million.
  • On December 9, 2020, Y-mAbs announced an update on DANYELZA data from the Companys Study 201, which was presented at the ESMO Immunocology-Oncology Virtual Congress 2020.
  • On November 25, 2020, Y-mAbs announced that the FDA had approved DANYELZA for the treatment relapsed or primary refractory high-risk neuroblastoma.

Y-mAbs Therapeutics to Present At 39th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 6, 2021
Life sciences, Biotechnology, Medical specialties, Biology, Immunology, Immune system, Monoclonal antibody, Biopharmaceutical, MAbs, Trubion

The presentation will take place on Tuesday, January 12, 2021, at 10:00 AM Eastern Standard Time.

Key Points: 
  • The presentation will take place on Tuesday, January 12, 2021, at 10:00 AM Eastern Standard Time.
  • Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer.
  • Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges.
  • Y-mAbs is a registered trademark of Y-mAbs Therapeutics, Inc.

Y-mAbs Announces Sale of Priority Review Voucher

Retrieved on: 
Monday, December 28, 2020
Academic journals, MAbs, Confirmatory trial, Publications, Periodicals

The transaction remains subject to customary closing conditions, including anti-trust review.

Key Points: 
  • The transaction remains subject to customary closing conditions, including anti-trust review.
  • We are pleased to announce the sale of the PRV, which will provide an important source of non-dilutive capital to fund additional investment in our pipeline.
  • As a result of this licensing arrangement, MSK has institutional financial interests related to the compound and Y-mAbs.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory trial.

Y-mAbs Announces Third Quarter 2020 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, November 5, 2020
Academic journals, Food and Drug Administration, Pharmaceuticals policy, Prescription Drug User Fee Act, MAbs, Publications, Periodicals

NEW YORK, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB) a development-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the third quarter 2020.

Key Points: 
  • NEW YORK, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB) a development-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the third quarter 2020.
  • We are very pleased with our third quarter 2020 financial results, especially seen in conjunction with the upcoming
    PDUFA date for naxitamab later this month, and the planned resubmission of the omburtamab BLA.
  • We believe that we are well positioned to transform Y-mAbs to a commercial-stage company, stated Thomas Gad, founder, Chairman and President.
  • To participate in the call, please dial 877-407-0792 (domestic) or 201-689-8263 (international) and reference the access code 13712633.

Y-mAbs to Announce Third Quarter 2020 Financial and Operating Results on November 5, 2020

Retrieved on: 
Thursday, October 29, 2020
Academic journals, Articles, Immune system, Communication, Forward-looking statement, Monoclonal antibody, MAbs, Trademark, Life sciences

The Company has a broad and advanced product pipeline, including two pivotal-stage product candidates naxitamab and omburtamab, which target tumors that express GD2 and B7-H3, respectively.

Key Points: 
  • The Company has a broad and advanced product pipeline, including two pivotal-stage product candidates naxitamab and omburtamab, which target tumors that express GD2 and B7-H3, respectively.
  • Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.
  • Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges.
  • Y-mAbs is a registered trademark of Y-mAbs Therapeutics, Inc.

Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma

Retrieved on: 
Monday, October 5, 2020
Medical specialties, Immunology, Medicine, Clinical medicine, Biotechnology, Immune system, Monoclonal antibody, Memorial Sloan Kettering Cancer Center, MAbs, MSK, Antibody

Y-mAbs will hold an investor conference call to discuss this update on October 6, 2020 at 9:00 a.m. EDT.

Key Points: 
  • Y-mAbs will hold an investor conference call to discuss this update on October 6, 2020 at 9:00 a.m. EDT.
  • Researchers at Memorial Sloan Kettering Cancer Center (MSK) developed omburtamab, which is exclusively licensed by MSK to Y-mAbs.
  • Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer.
  • Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges.

Y-mAbs Announces Second Quarter 2020 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, August 6, 2020
Life sciences, Biotechnology, Health, Articles, Pharmaceutical industry, Immune system, Immunology, Monoclonal antibody, Biopharmaceutical, MAbs

NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the second quarter 2020.

Key Points: 
  • NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the second quarter 2020.
  • We are very pleased with our second quarter 2020 financial results, especially seen in conjunction with the recent completion of our omburtamab BLA submission to the FDA.
  • We were very pleased to designate the first four SADA constructs for preclinical development and hope to file the first IND next year.
  • The Company will host a conference call on Friday, August 7, 2020 at 9 am eastern time.

Y-mAbs enters into Worldwide Exclusive License Agreement for SADA Technology – a Novel Radioimmunotherapy Platform

Retrieved on: 
Wednesday, April 15, 2020
Immunology, Branches of biology, Biology, Life sciences, Radioimmunotherapy, Monoclonal antibody, Antibody, C-Met, MAbs

The SADA technology utilizes a targeted payload delivery method where antibody constructs assemble in tetramers and bind to the tumor target.

Key Points: 
  • The SADA technology utilizes a targeted payload delivery method where antibody constructs assemble in tetramers and bind to the tumor target.
  • The SADA technology was invented by Nai-Kong V. Cheung, M.D., Ph.D., Mahiuddin Ahmed, Ph.D. and Brian Santich, Ph.D. and adapted for radioimmunotherapy by Steven M. Larson, M.D.
  • I am excited to enter into this agreement with MSK and MIT to expand Y-mAbs antibody platform with this promising technology.
  • I dont believe the tumor-to-blood standard uptake ratios obtained in animal models based on the SADA technology have ever been seen before.

Y-mAbs to Host R&D Event and Live Webcast on Wednesday, December 11

Retrieved on: 
Thursday, December 5, 2019
Biotechnology, Academic journals, Immunology, Life sciences, Biology, Immune system, Monoclonal antibody, MAbs, GD2

Modak, Kramer, and Mora will be available to answer questions at the conclusion of the event.

Key Points: 
  • Modak, Kramer, and Mora will be available to answer questions at the conclusion of the event.
  • Y-mAbs management will also provide an in-depth overview of the Companys broad and advanced product pipeline as well as a review of recent corporate and clinical developments.
  • Y-mAbs is advancing two pivotal-stage product candidates, naxitamab and omburtamab, targeting tumors that express GD2 and B7-H3, respectively.
  • Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer.